1	Membrane-Localized Mutations Predict the
2	Efficacy of Cancer Immunotherapy
3	
4	Priscilla S. Briquez <sup>1+</sup> , Sylvie Hauert <sup>1</sup> *, Zoe Goldberger <sup>1,2</sup> *, Trevin Kurtanich <sup>1</sup> ,
5	Aaron T. Alpar <sup>1</sup> , Grégoire Repond <sup>1</sup> , Yue Wang <sup>1</sup> , Suzana Gomes <sup>1</sup> , Prabha
6	Siddarth <sup>3</sup> , Melody A. Swartz <sup>1,4,5,6</sup> , Jeffrey A. Hubbell <sup>1,5,6+</sup>
7	
8	* These authors contributed equally to this work
9	<sup>+</sup> Correspondence: jhubbell@uchicago.edu, pbriquez@uchicago.edu
10	
11	Affiliations:
12	<sup>1</sup> Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA
13	<sup>2</sup> Department of Bioengineering, McGill University, Montreal, QC, Canada
14	<sup>3</sup> Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, CA, USA
15	<sup>4</sup> Ben May Department of Cancer Research, University of Chicago, Chicago, IL, USA
16	<sup>5</sup> Committee on Immunology, University of Chicago, Chicago, IL, USA
17	<sup>6</sup> Committee on Cancer Biology, University of Chicago, Chicago, IL, USA
18	

## 19 SUPPLEMENTARY INFORMATION

- 20
- Supplementary Data 1: Subcellular locations of proteins associated with Homo
  Sapiens genes.
- Supplementary Data 2: Proportion of mutations at specific location for ICI-treated
  cohort from Samstein *et al.*<sup>7</sup>
- 25 Supplementary Data 3: Proportion of mutations at specific location for the non-ICI-
- treated cohort from Samstein *et al.*<sup>7</sup>
- 27 **Supplementary Data 4:** Proportion of mutations at specific location for the NSCLC
- 28 patients cohort from Hellman *et al.*<sup>8</sup>
- Supplementary Data 5: Proportion of mutations at specific location for the
  melanoma patients cohort from Hugo *et al.*<sup>9</sup>
- 31 **Supplementary Data 6:** HR of survival per mutated genes and per cancer type for
- 32 the ICI and non-ICI treated patients cohort from Samstein *et al.*<sup>7</sup>
- 33
- 34
- 35





Supplementary Fig. 1. Characterization of OVA-expressing B16-F10 melanoma cell 38 lines and tumors. a, Design of the different OVA-expressing B16-F10 cell lines, expressing 39 membrane OVA (mOVA) or soluble OVA. b, OVA expression in the modified B16 cell lines in 40 41 culture in vitro, assessed by qPCR (N≥6, mean ± SD, ANOVA with Sidak's post-test). c, OVA 42 expression in the modified B16 tumors in vivo, assessed by qPCR (N≥4, mean ± SD, ANOVA with Sidak's post-test). d, Cell-surface staining of OVA quantified by flow cytometry via the 43 mean fluorescence intensity. e, Detection of cell plasma membrane-bound OVA on the 44 different OVA-expressing B16 cell lines assessed by microscopy (red: anti-OVA; scale bar = 45 50 µm). f, Western blot analysis for OVA detection in the extracellular vesicles (EV) produced 46 in vitro by B16mOVA<sup>HI</sup> or B16-OVA<sup>HI</sup> cells lines or in the non-EV fraction (black = positive 47 detection of OVA). g, Survival of mice injected with the different OVA-expressing cell lines, 48 associated to the tumor growth curves of Fig. 1a (N≥8, log-rank tests with Holm-Bonferroni p-49 values adjustment). h, Tumor growth of B16mOVA<sup>HI</sup> in Act-mOVA mice as compared to 50 growth in wild-type (WT) mice (N≥3, mean ± SEM, Kruskal-Wallis with Dunn's post-test at day 51 10). 52

53



Supplementary Fig. 2. Gating strategy for the characterization of T and NK cells. Multi-colored flow cytometry was used to analyze the subsets of T and NK cells in the tumors at day 10 post-injection. Subset of immune cells were defined using the following markers: NK cells (FSC<sup>LO</sup>, SSC<sup>LO</sup>, CD45<sup>+</sup>, NK1.1<sup>+</sup>, CD3ε<sup>-</sup>), NK T cells (FSC<sup>LO</sup>, SSC<sup>LO</sup>, CD45<sup>+</sup>, CD3ε<sup>+</sup>, NK1.1<sup>+</sup>), CD8<sup>+</sup> T cells (FSC<sup>LO</sup>, SSC<sup>LO</sup>, CD45<sup>+</sup>, NK1.1<sup>-</sup>, CD3ε<sup>+</sup>, CD8<sup>+</sup>), CD4+ T cells (FSC<sup>LO</sup>, SSC<sup>LO</sup>, CD45<sup>+</sup>, NK1.1<sup>-</sup>, CD3ε<sup>+</sup>, CD8<sup>+</sup>), effector T cells (same markers than T cells with CD44<sup>+</sup>, CD62L<sup>-</sup>), effector memory T cells (same markers than T cells with CD44<sup>+</sup>, CD62L<sup>+</sup>). regulatory T cells (same as CD4<sup>+</sup> T cells with CD25<sup>+</sup>, FoxP3<sup>+</sup>). 



Supplementary Fig. 3. Gating strategy for the characterization of B cells and myeloid cell subsets. Multi-colored flow cytometry was used to analyze the subsets of B cells and myeloid cells in the tumors at day 10 post-injection. Subset of immune cells were defined using the following markers: Macrophages (CD45<sup>+</sup>, F4/80<sup>+</sup>, CD11b<sup>+</sup>), Granylocytic myeloid-derived suppressor cells (MDSC) (CD45<sup>+</sup>, F4/80<sup>-</sup>, CD3<sup>2</sup>, Ly6G<sup>+</sup>, Ly6C<sup>MID/HI</sup>), Monocytic MDSC (CD45<sup>+</sup>, F4/80<sup>-</sup>, CD3ε<sup>-</sup>, Ly6G<sup>-</sup>, Ly6C<sup>HI</sup>), B cells (CD45<sup>+</sup>, F4/80<sup>-</sup>, CD3ε<sup>-</sup>, Ly6G<sup>-</sup>, Ly6C<sup>LO/MID</sup>, CD19<sup>+</sup>, B220<sup>+</sup>), dendritic cells (DCs) (CD45<sup>+</sup>, F4/80<sup>-</sup>, CD3ε<sup>-</sup>, Ly6G<sup>-</sup>, Ly6C<sup>LO/MID</sup>, CD11c<sup>+</sup>, MHCII<sup>+</sup>), CD11b<sup>+</sup> DCs (same than DCs with CD11b<sup>+</sup>), CD103<sup>+</sup> DCs (same than DCs with CD11b<sup>-</sup>, B220<sup>-</sup>, CD103<sup>+</sup>). 



81 Supplementary Fig. 4. Comparison of B16mOVA and B16-OVA melanoma tumor 82 immunogenicity and responsiveness to cancer immunotherapy in mice. a-e, Flow cytometry analysis of immune cells infiltrated in tumors 10 days post-injection (N≥4, mean ± 83 SD, ANOVA with Tukey's post-test and Brown-Forsythe correction when needed). a, Number 84 of CD45<sup>+</sup> immune cells and CD8<sup>+</sup> T cells per mg of tumor. b, CD8<sup>+</sup> and c, CD4<sup>+</sup> effector and 85 effector memory T cells subsets in the different tumors. d, Proportion of PD-1 expressing 86 CD8<sup>+</sup> and CD4<sup>+</sup> T cells. e, Proportion of NK T cells, B cells, dendritic cells, macrophages and 87 myeloid-derived suppressor cells relative to the total CD45<sup>+</sup> immune cell populations. f, Titers 88 (log<sub>10</sub>) of the anti-OVA measured per IgG subtype in the plasma of tumor-bearing mice at day 89 10, which corresponds Fig. 1d. (N≥4, mean ± SD, Kruskal-Wallis with Dunn's post-test per 90 IgG subtype). g, Tumor growth and associated survival of OVA-expressing tumor-bearing 91 mice treated with 100 µg of anti-PD-L1 and 100 µg of anti-CTLA-4 injected intraperitoneally 92 when the tumor volume reached 20-50 mm<sup>3</sup> (grey thresholds) (N≥3, mean  $\pm$  SEM, log-rank 93 tests). h, Survival of mice re-challenged with B16-F10 WT tumor cells, associated to the 94 95 tumor growth curves presented in Fig. 1i (N≥8, mean ± SEM, log-rank test).



Supplementary Data Fig. 5. Analysis of tumor mutated genes' subcellular localizations and 98 their subsequent impact on patient survival. a, Number of tumor mutated genes associated 99 with each subcellular location among the 469 genes sequenced by MSK-IMPACT method. 100 b, Proportion of tumor mutated genes per subcellular location in patients treated with 101 102 immunotherapy in the pan-cancer group, and corresponding percentile cutoff values used for the analysis in Fig. 2. c, Survival of ICI-treated patients harboring high (Top 50% or 10%) or 103 low (Bottom 50% or 10%) mTMB (log-rank tests). d, Increase in risk of death as a function of 104 mTMB in ICI-treated patients in the pan-cancer group. Values are calculated as 100\*(HR-1) ± 105 106 95% CI with HR the hazard ratio for survival of patients that have less than the depicted 107 proportion as compared to those that have more. As an example, ICI-treated patients that had less than Q1=23% of mutated genes at the membrane had a 50% increased risk of death as 108 compared to those that have more than 23% membrane mutated genes (log-rank tests, red 109 values = p-value  $\leq$  0.05, grey values = not significant). **e**, Survival of ICI-treated patients with 110 high (Top 25%) mTMB and sTMB (log-rank test). 111



Hazard ratio analysis of high vs. low mTMB per cancer type

	THRESHOLD USING UNIVERSAL CUTOFF VALUES					
	Hazard	95% CI	95% CI		Number of patients	
	ratio	upper limit	lower limit	p-value	Total (bottom vs. top)	
Pan-Cancer	0.661	0.798	0.547	1.45E-05	832 (404 vs. 428)	
Bladder Cancer	1.192	2.343	0.607	0.6095	104 (84 vs. 21)	
Breast Cancer	1.949	5.079	0.748	0.1647	26 (17 vs. 9)	
Colorectal Cancer	1.015	2.732	0.377	0.9768	51 (10 vs. 41)	
Esophagogastric Cancer	0.562	1.207	0.261	0.1343	75 (46 vs. 29)	
Glioma	0.785	1.565	0.394	0.4914	71 (58 vs. 13)	
Head and Neck Cancer	0.792	1.483	0.423	0.4657	73 (48 vs. 25)	
Melanoma	0.700	1.239	0.395	0.2183	143 (30 vs. 113)	
Non-Small Cell Lung Cancer	0.826	1.233	0.553	0.3483	156 (62 vs. 94)	
Renal Cell Carcinoma	0.351	0.690	0.178	0.0015	83 (26 vs. 57)	

THRESHOLD USING 25% TOP vs. 25% BOTTOM

-				
Hazard ratio	95% CI upper limit	95% CI Iower limit	p-value	Number of patients Total (bottom vs. top)
0.661	0.798	0.547	1.45E-05	832 (404 vs. 428)
0.843	1.449	0.491	0.5369	110 (57 vs. 53)
1.639	4.261	0.630	0.3061	26 (12 vs. 14)
1.353	2.748	0.666	0.4007	69 (28 vs. 41)
0.477	1.090	0.209	0.0731	60 (30 vs. 30)
1.194	2.004	0.712	0.5013	82 (43 vs. 39)
0.459	0.863	0.244	0.0135	67 (34 vs. 33)
0.827	1.295	0.528	0.4052	175 (95 vs. 80)
0.959	1.394	0.660	0.8277	180 (86 vs. 94)
0.604	1.142	0.319	0.1168	102 (45 vs. 57)

113 114 с

Supplementary Fig. 6. Distributions of patients by cancer types and according to their mTMB. a, Distribution of the ICI-treated patients per cancer type included in the pan-cancer analysis. b, Differences in patient distribution per cancer type for the groups with high (Top 25%) or low (Bottom 25%) mTMB, as compared to the distribution of the entire ICI-treated cohort as in panel a. c, Values of the HRs, 95% confidence intervals, p-value of the log-rank tests and number of patients used in Fig. 3b, for the universal cutoff and the 25% top vs. bottom strategies.



Supplementary Fig. 7. Response to immunotherapy based on the proportion of 124 mutated genes at specific subcellular localizations. Patients (N=75) with non-small cell 125 lung cancer were treated with anti-PD-1 + anti-CTLA-4 in the cohort from Hellman et al.<sup>8</sup>, and 126 127 patients (N=38) with advanced melanoma cancer were treated with anti-PD-1 in the cohort from Hugo et al.9. In both studies, tumor mutated genes were sequenced by the WES 128 method. a, Number of tumor mutated genes detected across all patients in the Hellman et al. 129 and Hugo et al. studies, respectively, and their associated subcellular locations. 130 b, Comparison of the mTMB found in ICI-treated patient cohorts from the studies by Samstein 131 132 et al.<sup>7</sup>, Hellman et al.<sup>8</sup> and Hugo et al.<sup>9</sup> c, Proportion of mutated genes per subcellular location 133 in patients that responded or not to immunotherapy in the Hellman et al. cohort (Mann-Whitney test). d, Survival of patients with high (Top 25% and 50%) or low (Bottom 25% and 134 50%) mTMB in the Hellman et al.<sup>8</sup> cohort (log-rank test). e, Same as in panel c, but with the 135

patient cohort from Hugo et al.<sup>9</sup> f, Proportion of responders or non-responders to anti-PD-1 136 among patients that have high (Top 25%) or low (Bottom 25%) mTMB in the Hugo et al.9 137 138 cohort (Fisher's exact test). g, Same as in panel d, but with the patient cohort from Hugo et al.9. h, Proportion of mutated genes at the cell plasma membrane or in other specific 139 140 membrane-containing cell organelles in responders and non-responders to immunotherapy from the Hugo *et al.*<sup>9</sup> **i**, Survival of the patients with high (Top 10%) or low (Bottom 10%) 141 proportion of mutated genes expressing proteins at the tumor cell plasma membrane for the 142 143 pan-cancer groups from the cohort from Samstein et al.7 144



Supplementary Fig. 8. Potential use of mTMB and specific membrane-associated 147 mutated genes as predictive clinical biomarkers for extended survival upon ICI. Data 148 analyzed from Samstein et al.7 ICI-treated or non-ICI-treated cohorts. a, Survival of patients 149 bearing at least one mutated genes among the cancer-specific list of genes highlighted in 150 blue in Fig. 5a, as compared to patients with no mutated genes among the list. b, Survival 151 curves of ICI and non-ICI treated patients bearing RNF43 mutations in colorectal cancer. 152 c, Survival curves of ICI and non-ICI treated patients bearing NOTCH1 mutations in NSCLC. 153 d, Comparison of survival of patients carrying RET mutations in NSCLC treated with ICI or 154 155 with a standard-of-care cabozantinib (data from Gautschi et al.<sup>25</sup>). e, Survival curves of patients from the pan-cancer group in function of their TMB level (in mut/Mbp). The higher the 156 TMB the longer the survival (log-rank test). f, Correlation between mTMB and total TMB. No 157 correlation was observed between these two parameters (Spearman correlation). 158 159